Effects of atorvastatin on serum hs-CRP,PAPP-A levels in acute coronary syndrome patients

Objective To investigate the effects of atorvastatin on serum high sensitive C-reactive protein(hs-CRP) and pregnancy-associated plasma protein-A(PAPP-A) levels in acute coronary syndrome(ACS) patients. Methods Serum hs-CRP and PAPP-A levels were measured in 37 patients with unstable angina(UAP),24 patients with acute myocardial infarction(AMI),29 patients with stable angina(SAP),and 32 healthy controls.Sixty-one ACS patients(UAP+AMI) were randomly assigned to conventional treatment group(n=30) or atorvastatin treatment group(n=31).Serum hs-CRP and PAPP-A levels were detected before and after treatment. Results ① hs-CRP and PAPP-A levels in ACS patients [UAP:(16.7±1.24)mg,(63.88±1.82)μg/L;AMI:(18.52±1.96)mg/L,(66.41±1.24)μg/L]were significantly higher than those in stable angina patients [(4.6±1.16) mg/L,(47.56±0.72) μg/L] and controls [(3.2±0.88) mg/L,(45.17±1.28) μg/L](all P0.05).②Serum hs-CRP and PAPP-A levels were significantly decreased after atorvastatin treatment in ACS group compared with baseline [hs-CRP(18.52±2.37)mg/L vs.(3.58±1.33) mg/L;PAPP-A(67.83±2.15) μg/L vs.(45.62±1.58) μg/L;both P0.05] and were also lower compared with conventional treatment group [hs-CRP(3.58±1.33)mg/L vs.(5.23±1.98)mg/L;PAPP-A(45.62±1.58) μg/L vs.(51.35±2.15) μg/L,both P0.05]. Conclusions Atorvastatin can reduce inflammatory reaction in atherosclerotic plaque in ACS patients and has an effect on plaque stabilization.